ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison

Area of Science:

• Cardiology
• Clinical Guidelines
• Evidence-Based Medicine

Background:

• Heart failure (HF) diagnosis and treatment are guided by major international bodies.
• The 2022 ACC/AHA/HFSA and 2021 ESC guidelines offer evidence-based recommendations.
• Recent updates include the Universal Definition of HF and new trial data.

Purpose of the Study:

• To compare the 2022 ACC/AHA/HFSA and 2021 ESC heart failure guidelines.
• To highlight differences in diagnosis, medical therapy, and device recommendations.
• To inform clinical practice and future guideline development.

Main Methods:

• Comparative review of the 2022 ACC/AHA/HFSA and 2021 ESC heart failure guidelines.
• Analysis of key recommendations, including diagnostic criteria, therapeutic strategies, and device indications.
• Identification of discrepancies and recent evidence incorporated into each guideline.

Main Results:

• Both guidelines utilize similar diagnostic approaches, including invasive and non-invasive testing.
• Differences noted in medical therapy and device recommendations, with ACC/AHA/HFSA incorporating recent trial data.
• ACC/AHA/HFSA guidelines emphasize quality of life and cost-effectiveness, while ESC guidelines address comorbidities.

Conclusions:

• The ACC/AHA/HFSA guidelines feature a notable recommendation for implantable cardioverter-defibrillators in HF with reduced ejection fraction (HFrEF).
• Discrepancies between guidelines may stem from recently published trials and differing emphasis on patient outcomes and comorbidities.
• This comparative analysis assists clinicians in tailoring treatment strategies and promotes harmonization in future guideline revisions.